InvestorsHub Logo

TheBioTechG

01/17/17 5:17 PM

#9408 RE: nsomniyak #9406

Gilead has already mentioned CytoDyn by name (albeit spelt wrong) as a potential disruptor to their HIV revenue stream:

http://marketstatsanalytics.com/gild_proscons3.html